

## Drugs Treatment

---

Reference Number: F4648  
Date of Response: 16<sup>th</sup> June 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### Royal Devon's Eastern FOI Office Response

How many patients has your trust treated in the past 6 months (for any disease) with the following drugs:

- 1) Aubagio (teriflunomide) - **45 Patients**
- 2) Avonex (interferon beta-1a) – **20 Patients**
- 3) Brabio (glatiramer acetate) – **0 Patients**
- 4) Copaxone (glatiramer acetate) – **32 Patients**
- 5) Extavia (beta interferon-1b) – **0 Patients**
- 6) Fampyra (fampridine) – **0 Patients**
- 7) Gilenya (fingolimod) – **21 Patients**
- 8) Lemtrada (alemtuzumab) – **0 Patients**
- 9) Kesimpta (ofatumumab) – **9 Patients**
- 10) Ocrevus (ocrelizumab) – **23 Patients**
- 11) Plegridy (peginterferon beta-1a) – **9 Patients**
- 12) Rebif (beta interferon-1a) – **0 Patients**
- 13) Tecfidera (dimethyl fumarate) – **111 Patients**
- 14) Tysabri (natalizumab) – **40 Patients**
- 15) Zeposia (ozanimod) – **0 Patients**

**In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:**

- Betaferon (interferon beta-1b)
- Mavenclad (cladribine)
- Mayzent (siponimod)

We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and principle One of the GDPR.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.